Crystal tombstone celebrating a favorable verdict in an antitrust action against Gilead Sciences. The claim had centered on an earlier patent settlement involving Gilead and Teva. (23AKL380)
Crystal tombstone celebrating a favorable verdict in an antitrust action against Gilead Sciences. The claim had centered on an earlier patent settlement involving Gilead and Teva. (23AKL380)
Lucite deal tombstone commemorating two related royatly transactions. Both deals involve the diabetes drug TZIELD. (23AKL274)
Lucite commemorative marking the first patient dosed in a clinical study involving LunAIRo. Developed by Apnimed, the drug is intended for the treatment of obstructive sleep apnea. (23AZH173)
Diamond-shaped crystal deal toy commemorating a follow-on stock offering by Swiss biotech firm Oculis. (23AKL262)
Custom Lucite with an embedded drug vial commemorating FDA approval of ELAHERE. Developed by ImmunoGen, the drug was granted accelerated FDA approval as a treatment for ovarian cancer. (23AKL266)
Lucite tombstone recognizing a registered direct offering by BioCardia. The Sunnyvale, California-based company develops cellular and cell-derived therapeutics for cardiovascular and pulmonary conditions. (23AKL286)
Lucite deal tombstone recognizing the merger of Adatptimmune and TCR2 Therapeutics. Both companies develop treatments that re-engineer immune cells to treat cancer. (23AKL209)
